- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Indegene Announces New Brand Expression
Brand refresh aligns with company‘s purpose to enable healthcare organizations to be “future ready.”
Indegene (Princeton, NJ), a technology-led healthcare solutions provider, has announced its new brand expression, aligned with its purpose to enable healthcare organizations to be “future ready.”
Indegene’s new logo and brand expression “reflects who it truly is...” the company stated. “It represents the convergence of healthcare and technology. It stands for the coming together of modern practices in healthcare operations, while retaining the best of the traditional ones. Together, these drive the industry towards future readiness.”
Manish Gupta, co-founder and CEO, Indegene, said, “From our founding days, we focused on building an organization dedicated to healthcare and one that modernizes its operating practices....Our brand purpose is a natural articulation of our founding principles.”
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
